Enhertu (trastuzumab deruxtecan)
pCPA File Number: 22045
Under consideration for negotiation
For the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received a prior treatment with an anti-HER2-based regimen in the metastatic setting or developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy
AstraZeneca Canada Inc.
CADTH Project Number:
pCPA Engagement Letter Issued:
Negotiation Process Concluded: